Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s.
Latest Company News - Investing.com investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.
Royal Bank of Canada reiterated their outperform rating on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a research note released on Friday morning, Benzinga reports. The firm currently has a $7.00 price objective on the stock. PYXS has been the topic of several other reports. Leerink Partnrs reissued an outperform rating on shares […]
Pyxis Oncology (NASDAQ:PYXS – Free Report) had its price target upped by HC Wainwright from $4.00 to $7.00 in a research report sent to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the stock. Other equities research analysts have also issued reports about the company. BTIG Research began coverage […]
Pyxis Oncology (NASDAQ:PYXS – Free Report) had its target price boosted by HC Wainwright from $4.00 to $7.00 in a report issued on Friday morning, Benzinga reports. They currently have a buy rating on the stock. Several other research firms also recently commented on PYXS. BTIG Research started coverage on Pyxis Oncology in a report […]